
The investigational weight loss drug showed substantial weight loss among people with obesity or overweight with or without T2D without plateaus.

The investigational weight loss drug showed substantial weight loss among people with obesity or overweight with or without T2D without plateaus.

Your daily dose of the clinical news you may have missed.

Millions of US adults could benefit from semaglutide treatment for diabetes, obesity, and/or CV disease but insurance isn't guaranteed and the drug is costly.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

AHA 2024. "...we did not anticipate this magnitude of increase in mortality," researchers said. They were also surprised by the population groups most affected.

Dual and triple incretin agonists continue to lead the new therapies in the antiobesity pipeline. Here is an at-a-glance update of their progress toward approval.

SYNCHRONIZE-1 and -2 will provide "robust evidence" on the safety, efficacy, and tolerability of survodutide in adults with obesity with or without T2D.

ObesityWeek 2024. Semaglutide 2.4 mg reduces rates of composite CV outcomes in high-risk patients without diabetes and now is shown to reduce inpatient care and length of stay.

Results from the VENTURE phase 2 trial and a phase I oral formulation study found that VK2735, a dual GLP-1 and GIP receptor agonist, demonstrated promise in treating obesity.

Clinicians should continue to monitor trade-offs between pharmacologic and surgical management of obesity, researchers said.

ACG 2024: New study results indicate GLP-1 RAs have a potentially protective role to play in combating EO-CRC, the incidence of which is notably rising worldwide.

Three-quarters of primary care survey respondents prescribe GLP-1 RAs for weight loss and half get questions daily about the drugs. See all the results.

Antiobesity medications are the next step after lifestyle interventions prove inadequate; here are the American Gastroenterological Association recommendations, at-a-glance.

In a study of adolescents with obesity, those in the GLP-1RA group had a 33% lower risk of experiencing suicidal ideation or attempts compared with matched controls.

Obesity is a complex disease that requires a multispecialty approach to address the physical and also the mental and emotional components of the widespread disorder.

Your daily dose of the clinical news you may have missed.

EASD 2024: Amycretin was also found to be safe and well tolerated in adults with obesity and without diabetes.

Your daily dose of the clinical news you may have missed.

EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.

Once-daily oral TERNS-601 was associated with a significant mean 5% weight reduction after 28 days and had a favorable tolerability profile.

Your daily dose of the clinical news you may have missed.

In a study of adolescents with obesity, symptoms of depression and eating disorders decreased over the course of a 52-week intensive behavioral intervention.

Vials of tirzepatide 2.5 mg and 5 mg will be available with a prescription for the labeled drug through LillyDirect after completing a multistep verification process, the company said.

Patients with obesity face both physical and emotional challenges during the COVID-19 pandemic. How can PCPs help?